Medpace, a privately held, global full-service clinical research organization, today announced it has entered into a purchase agreement to acquire Pharma Brains AG, an oncology focused CRO based in Basel, Switzerland.
Pharma Brains is an excellent fit with Medpace in terms of its complementary therapeutic expertise, strong leadership and qualified staff. Pharma Brains is led by Dr. Marc Salzberg, President and CEO, a research professional with extensive experience in oncology Phase I-IV studies as well as drug development and regulatory affairs.
"I am pleased to have Dr. Salzberg joining the group as an integral leader beginning with the integration and going forward as the VP of Oncology, Europe and General Manager, Switzerland," said Dr. August Troendle, President and CEO, Medpace. "Marc Salzberg is a distinguished professional in European drug development and brings 17 years of industry and leadership experience to Medpace."
The integration of Pharma Brains operations will begin immediately with the intent of completing the merger by the end of 2009.
New research explores how antimicrobial exposure affects Parkinson’s disease risk